Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC)

Vanessa Wong; Wei Hong; Sumitra Ananda; Catherine Dunn; Rachel Wong; Yat Hang To; Matthew E Burge; Louise M Nott; Jeanne Tie; Jeremy David Shapiro; Ross Jennens; Muhammad Adnan Khattak; Aflah Roohullah; Peter Gibbs

Conference Proceedings

Options beyond BRAF targeted therapy in second-line treatment of patients with BRAFV600E mutant (BRAFmt) metastatic colorectal cancer (mCRC)

Vanessa Wong, Wei Hong, Sumitra Ananda, Catherine Dunn, Rachel Wong, Yat Hang To, Matthew E Burge, Louise M Nott, Jeanne Tie, Jeremy David Shapiro, Ross Jennens, Muhammad Adnan Khattak, Aflah Roohullah, Peter Gibbs

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2022

DOI: 10.1200/JCO.2022.40.4_suppl.047

Abstract

47 Background: BRAFmt is a negative prognostic factor in mCRC but also identifies a patient population that may benefit from BRAF targeted therapy. Results from recent trials (BEACON and SWOG1406) demonstrate improved survival outcomes in second- and third-line settings when combining a BRAF inhibitor, an EGFR inhibitor (EGFRi) +/- a MEK inhibitor. In both trials, irinotecan and cetuximab was the control arm with a dismal response rate of 2-4% and progression free survival (PFS) of only 2 months. This suggests chemotherapy plus an EGFRi may not be the optimal approach where BRAF-targeted therapies are not available or have failed. Methods: Data from July 2009 to September 2021 was analysed ..

View full abstract